Ubs Group Ag Moleculin Biotech, Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	BUY	$0.38 - $0.72 $76 - $144	200 New	200 $0
Q4 2022 Feb 08, 2023	BUY	$0.85 - $16.65 $679 - $13,303	799 Added 7.65%	11,243 $11,000
Q3 2022 Nov 10, 2022	BUY	$1.15 - $17.4 $10,109 - $152,963	8,791 Added 531.82%	10,444 $11,000
Q2 2022 Aug 10, 2022	BUY	$1.19 - $2.0 $1,967 - $3,306	1,653 New	1,653 $2,000
Q4 2021 Feb 14, 2022	SELL	$1.64 - $2.83 $2,300 - $3,970	-1,403 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$2.7 - $3.59 $896 - $1,191	332 Added 31.0%	1,403 $4,000
Q2 2021 Aug 13, 2021	BUY	$3.21 - $4.06 $3,437 - $4,348	1,071 New	1,071 $4,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $48.6M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.